| Literature DB >> 21541793 |
Andreas Reiff1, Bracha Shaham, Kenneth I Weinberg, Gay M Crooks, Robertson Parkman.
Abstract
Autologous hematopoietic stem cell transplantation (HSCT) has been used for the treatment of both adult and pediatric autoimmune diseases. However, HSCT has significant side effects (neutropenia, thrombocytopenia, infertility, cardiotoxicity) and costs (HSC collection/harvesting, blood product support). In an attempt to avoid the toxicities and costs associated with HSCT, we investigated whether immune ablation similar to that achieved following myeloablative HSCT could be achieved by the intensive administration of an anti-CD52 antibody (Campath-1H antibody). The first patient treated with the treatment regime, who had refractory juvenile polymyositis, achieved immune ablation (the elimination of pre-therapy antigen-specific T lymphocyte immunity) and has had stable clinical improvement for more than 6 years.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21541793 DOI: 10.1007/s10875-011-9533-7
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317